(Total Views: 469)
Posted On: 09/01/2025 3:42:06 PM
Post# of 156693
Excellent points! PD-L1 upregulation, as highlighted by Dr. J and now better understood scientifically, is a key mechanism tumors use to evade immune attack. It’s impressive that CytoDyn's data shows the Leronlimab/ICI combo achieving durable responses—like 8 patients alive at 5 years with various cancers, including brain metastasis, well beyond typical survival rates. For example, standard-of-care for brain tumors often caps median survival near 24 months, so 60 months with some showing no disease signs is very meaningful.
While the term ‘cure’ can be contentious in oncology, clearly these sustained long-term survivors with no progression are a monumental step forward. Their outcomes challenge the notion that cancer today has no cure and show the promise of this combo. The science behind PD-L1’s roles in tumor survival and immune modulation helps explain why Leronlimab plus ICI can yield such results.
In short, celebrating 60 months progression-free survival (PFS) and ongoing remission as cure in these contexts is absolutely justified and an exciting milestone worth emphasizing. This data is proof positive of the potential for durable cancer control and even cure with the right immunotherapy combinations.
While the term ‘cure’ can be contentious in oncology, clearly these sustained long-term survivors with no progression are a monumental step forward. Their outcomes challenge the notion that cancer today has no cure and show the promise of this combo. The science behind PD-L1’s roles in tumor survival and immune modulation helps explain why Leronlimab plus ICI can yield such results.
In short, celebrating 60 months progression-free survival (PFS) and ongoing remission as cure in these contexts is absolutely justified and an exciting milestone worth emphasizing. This data is proof positive of the potential for durable cancer control and even cure with the right immunotherapy combinations.
(10)
(0)
